A multicenter, multinational retrospective study to evaluate the patterns of use for loxapine [Adasuve] in real-world settings

Trial Profile

A multicenter, multinational retrospective study to evaluate the patterns of use for loxapine [Adasuve] in real-world settings

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2015

At a glance

  • Drugs Loxapine (Primary)
  • Indications Agitation
  • Focus Therapeutic Use
  • Acronyms DUS
  • Sponsors Alexza Pharmaceuticals
  • Most Recent Events

    • 18 Jun 2015 According to a media release, Alexza Pharmaceuticals plans to transfer the EU Marketing authorization for ADASUVE (MAA) to Ferrer. The MAA transfer includes the responsibilities for the ongoing post-approval clinical studies (the PASS and DUS studies), a planned phase III trial in adolescents [see CT profile 700257964] and ongoing pharmacovigilance responsibilities.
    • 14 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top